Results:
A total of 86 cases were enrolled including 57 males and 29 females with a median age of 35 months (range 1 month to 198 months). And 11 cases were categorized as the mild-moderate group and 75 cases were categorized as the severe group based on bleeding severity score. The positive rates were 68.6% for anti-GPIIb/IIIa and 65.1% for anti-GPIb/IX. There was no significant difference in anti-GPIIb/IIIa and anti-GPIb/IX antibodies between the two bleeding severity groups (χ2 =0.530, P =0.467;χ2 <0.001, P =1.000), and also no difference was found between the two groups when two antibodies were analyzed together (χ2 =2.071, P =0.558). The antibody titers in plasma and eluent were also detected, but no significant difference was found in the antibody titer ratios between the two bleeding severity groups (P <0.05 in four plasma and eluent groups).